88 related articles for article (PubMed ID: 22012946)
1. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.
Smith MA; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Morton CL; Wu J; Smith PG; Yu J; Houghton PJ
Pediatr Blood Cancer; 2012 Aug; 59(2):246-53. PubMed ID: 22012946
[TBL] [Abstract][Full Text] [Related]
2. AKT inhibitor MK-2206 sensitizes breast cancer cells to MLN4924, a first-in-class NEDD8-activating enzyme (NAE) inhibitor.
Chen X; Cui D; Bi Y; Shu J; Xiong X; Zhao Y
Cell Cycle; 2018; 17(16):2069-2079. PubMed ID: 30198810
[TBL] [Abstract][Full Text] [Related]
3. Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924.
Liao H; Liu XJ; Blank JL; Bouck DC; Bernard H; Garcia K; Lightcap ES
Mol Cell Proteomics; 2011 Nov; 10(11):M111.009183. PubMed ID: 21873567
[TBL] [Abstract][Full Text] [Related]
4. Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.
Czuczman NM; Barth MJ; Gu J; Neppalli V; Mavis C; Frys SE; Hu Q; Liu S; Klener P; Vockova P; Czuczman MS; Hernandez-Ilizaliturri FJ
Blood; 2016 Mar; 127(9):1128-37. PubMed ID: 26675347
[TBL] [Abstract][Full Text] [Related]
5. Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.
Kolb EA; Gorlick R; Keir ST; Maris JM; Lock R; Carol H; Kurmasheva RT; Reynolds CP; Kang MH; Wu J; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2012 May; 58(5):815-8. PubMed ID: 22052798
[TBL] [Abstract][Full Text] [Related]
6. Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses
Cooper J; Xu Q; Zhou L; Pavlovic M; Ojeda V; Moulick K; de Stanchina E; Poirier JT; Zauderer M; Rudin CM; Karajannis MA; Hanemann CO; Giancotti FG
Mol Cancer Ther; 2017 Aug; 16(8):1693-1704. PubMed ID: 28468780
[TBL] [Abstract][Full Text] [Related]
7. Initial testing of lenalidomide by the pediatric preclinical testing program.
Reynolds CP; Kang MH; Keir ST; Gorlick R; Kolb EA; Lock R; Maris JM; Carol H; Morton CL; Billups CA; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2011 Oct; 57(4):606-11. PubMed ID: 21360651
[TBL] [Abstract][Full Text] [Related]
8. The NEDD8 activating enzyme inhibitor MLN4924 mitigates doxorubicin-induced cardiotoxicity in mice.
Chen KH; Sun JM; Lin L; Liu JW; Liu XY; Chen GD; Chen H; Chen ZY
Free Radic Biol Med; 2024 Jul; 219():127-140. PubMed ID: 38614228
[TBL] [Abstract][Full Text] [Related]
9. Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.
Kang MH; Reynolds CP; Kolb EA; Gorlick R; Carol H; Lock R; Keir ST; Maris JM; Wu J; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2016 Oct; 63(10):1744-52. PubMed ID: 27238606
[TBL] [Abstract][Full Text] [Related]
10. Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.
Morton CL; Maris JM; Keir ST; Gorlick R; Kolb EA; Billups CA; Wu J; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2012 Apr; 58(4):566-71. PubMed ID: 21538824
[TBL] [Abstract][Full Text] [Related]
11. Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program.
Kurmasheva RT; Kurmashev D; Reynolds CP; Kang M; Wu J; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28921800
[TBL] [Abstract][Full Text] [Related]
12. The Neddylation Inhibitor Pevonedistat (MLN4924) Suppresses and Radiosensitizes Head and Neck Squamous Carcinoma Cells and Tumors.
Vanderdys V; Allak A; Guessous F; Benamar M; Read PW; Jameson MJ; Abbas T
Mol Cancer Ther; 2018 Feb; 17(2):368-380. PubMed ID: 28838998
[TBL] [Abstract][Full Text] [Related]
13. PTEN loss drives resistance to the neddylation inhibitor MLN4924 in glioblastoma and can be overcome with TOP2A inhibitors.
Ferdosi SR; Taylor B; Lee M; Tang N; Peng S; Bybee R; Reid G; Hartman L; Garcia-Mansfield K; Sharma R; Pirrotte P; Ma J; Parisian AD; Furnari F; Dhruv HD; Berens ME
Neuro Oncol; 2022 Nov; 24(11):1857-1868. PubMed ID: 35305088
[TBL] [Abstract][Full Text] [Related]
14. Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program.
Keir ST; Morton CL; Wu J; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2012 Sep; 59(3):586-8. PubMed ID: 22190407
[TBL] [Abstract][Full Text] [Related]
15. Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy.
Aubry A; Yu T; Bremner R
Cell Death Discov; 2020; 6():2. PubMed ID: 32123578
[No Abstract] [Full Text] [Related]
16. HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias.
Mshaik R; Simonet J; Georgievski A; Jamal L; Bechoua S; Ballerini P; Bellaye PS; Mlamla Z; Pais de Barros JP; Geissler A; Francin PJ; Girodon F; Garrido C; Quéré R
Blood Cancer J; 2021 Mar; 11(3):61. PubMed ID: 33737511
[TBL] [Abstract][Full Text] [Related]
17. In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenografts.
Randall J; Evans K; Watts B; Kosasih HJ; Smith CM; Earley EJ; Erickson SW; Jocoy EL; Bult CJ; Teicher BA; de Bock CE; Smith MA; Lock RB
Exp Hematol; 2024 Apr; 132():104176. PubMed ID: 38320689
[TBL] [Abstract][Full Text] [Related]
18. Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design.
Rokita JL; Rathi KS; Cardenas MF; Upton KA; Jayaseelan J; Cross KL; Pfeil J; Egolf LE; Way GP; Farrel A; Kendsersky NM; Patel K; Gaonkar KS; Modi A; Berko ER; Lopez G; Vaksman Z; Mayoh C; Nance J; McCoy K; Haber M; Evans K; McCalmont H; Bendak K; Böhm JW; Marshall GM; Tyrrell V; Kalletla K; Braun FK; Qi L; Du Y; Zhang H; Lindsay HB; Zhao S; Shu J; Baxter P; Morton C; Kurmashev D; Zheng S; Chen Y; Bowen J; Bryan AC; Leraas KM; Coppens SE; Doddapaneni H; Momin Z; Zhang W; Sacks GI; Hart LS; Krytska K; Mosse YP; Gatto GJ; Sanchez Y; Greene CS; Diskin SJ; Vaske OM; Haussler D; Gastier-Foster JM; Kolb EA; Gorlick R; Li XN; Reynolds CP; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB; Raman P; Wheeler DA; Maris JM
Cell Rep; 2019 Nov; 29(6):1675-1689.e9. PubMed ID: 31693904
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis.
Murphy B; Yin H; Maris JM; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Keir ST; Kurmasheva RT; Dvorchik I; Wu J; Billups CA; Boateng N; Smith MA; Lock RB; Houghton PJ
Cancer Res; 2016 Oct; 76(19):5798-5809. PubMed ID: 27496711
[TBL] [Abstract][Full Text] [Related]
20. Comment on: In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts.
Lewis WS; Kang J
Pediatr Blood Cancer; 2023 Dec; 70(12):e30673. PubMed ID: 37705152
[No Abstract] [Full Text] [Related]
[Next] [New Search]